TerminatedPhase 2

Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation

Stopped: undefined

Mexico50 participantsStarted 2008-08

Plain-language summary

The purpose of this study is to determine whether topical nepafenac (qid) is effective in preventing and treating macular thickening related pan-retinal photocoagulation in patients with diabetic retinopathy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with Severe and proliferative Diabetic Retinopathy * Symmetric severity grade on both eyes * Best corrected visual acuity better than 20/80 Exclusion Criteria: * Clinical significant macular edema * Lens opacity * Ocular surgery 6 months or less before recruit * Uveitis history * Actual use of topical or systemic non-steroidal anti inflammatory agents * Actual or history of other macular diseases * Ocular surface diseases * Vitreomacular traction syndrome * Other vascular retinal diseases different to diabetic retinopathy * Actual or history of use of topical prostaglandin analogues

What they're measuring

Central macular thickening

Timeframe: 2 weeks after each laser session and 1 and 2 months after last laser session

Trial details

NCT IDNCT00801905

SponsorAsociación para Evitar la Ceguera en México

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-12

View on ClinicalTrials.gov More Macular Thickening trials